Portal de Periódicos da CAPES

Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag

2021; Elsevier BV; Volume: 3; Issue: 2 Linguagem: Inglês

10.1016/j.jhepr.2021.100228

2589-5559

Robert S. Brown, Michio Imawari, Namiki Izumi, Yukio Osaki, Roy Bentley, Toshimitsu Ochiai, Takeshi Kano, Markus Peck‐Radosavljevic,

Hemophilia Treatment and Research

Despite limitations, platelet transfusion has been used to minimise bleeding risk in patients with thrombocytopaenia. Lusutrombopag is an oral, thrombopoietin receptor agonist approved for treatment of thrombocytopaenia associated with chronic liver disease in patients undergoing planned invasive procedures. This